Constipation in children

DEFINITION & EPIDEMIOLOGY

• Delay or difficulty in defecation causing significant distress.
• Functional Constipation (FC): Absence of underlying organic pathology; accounts for >95% of pediatric cases.
• Prevalence: Global pooled prevalence 9.5% (range 0.5–32.2%).
• Incidence Peaks: Initiation of solid foods, toilet training, starting school.

DIAGNOSTIC CRITERIA (ROME IV)

Diagnosis requires symptom duration of at least 1 month.

Age Group	Rome IV Criteria (Requires $\ge$2 criteria)
Infants up to 4 years	- $\le$2 defecations per week.- History of excessive stool retention.- History of painful/hard bowel movements.- History of large-diameter stools.- Presence of large rectal fecal mass.(If toilet trained: $\ge$1 episode/week of incontinence, large stools obstructing toilet).
Children $\ge$4 years	- $\le$2 defecations in the toilet per week.- $\ge$1 episode of fecal incontinence per week.- History of retentive posturing/volitional stool retention.- History of painful/hard bowel movements.- Presence of large rectal fecal mass.- History of large-diameter stools obstructing toilet.

ETIOLOGY & RISK FACTORS

Organic Causes (<5% of cases)

Category	Specific Conditions
Anatomical	Anorectal malformations, imperforate anus, anal stenosis, intestinal obstruction.
Neurogenic	Hirschsprung disease, spinal cord abnormalities (tethered cord, spina bifida), pseudo-obstruction, neuronal intestinal dysplasia.
Endocrine/Metabolic	Hypothyroidism, cystic fibrosis, celiac disease, hypokalemia, hypercalcemia, diabetes mellitus.
Medications/Toxins	Opiates, anticholinergics, antidepressants, chemotherapy, lead toxicity.

Risk Factors for Functional Constipation

Category	Identified Factors
Diet & Lifestyle	Low fiber intake, poor fluid intake, fast food consumption, decreased physical activity, poor sleep.
Psychological	Home/school stress, abuse, bullying, anxiety, depression, autism spectrum disorders, ADHD.

PATHOPHYSIOLOGY

Pathogenesis is multifactorial, involving behavioral, sensory, and motor components.

Infants and Young Children (Stool Withholding)

• Triggered by prior painful/frightening defecation.
• Voluntary/subconscious gluteal contraction and tiptoeing to prevent stool passage.
• Retained stool leads to increased rectal compliance and desensitization.
• Absorption of colonic water causes dry, hard stool, perpetuating pain and reinforcing withholding (vicious cycle).
• Pelvic Floor Dyssynergia (Anismus): Paradoxical contraction of external anal sphincter and pelvic floor during defecation; present in ~40% of constipated children.

Older Children and Adolescents (Colonic Dysmotility & Sensation)

• Delayed Colonic Transit: Reduced frequency or premature termination of high-amplitude propagating contractions (HAPCs).
• Sensory Abnormalities: Decreased rectal sensitivity to distension, leading to absent urge to defecate.
• Occult Reflex: Fecal impaction triggers rectal mucosal mechanoreceptors, activating myenteric descending nitrergic pathways. Nitric oxide release inhibits colonic contractile activity, hampering evacuation.
• Microbiome: Altered gut microbiota may modulate motility via fermentation products/osmotic effects.

CLINICAL EVALUATION

History

• Assess onset timing (early neonatal onset suggests Hirschsprung disease).
• Evaluate stool consistency utilizing validated scales (Bristol Stool Scale).
• Document retentive posturing, fecal incontinence (overflow soiling), abdominal pain, poor appetite, nausea, and vomiting.
• Screen for psychological distress, school absenteeism, bullying.

Alarm Symptoms (Red Flags)

Category	Alarm Signs Mandating Investigation
Neonatal	Delayed meconium >48 hours, very early-onset constipation (<1 month).
Gastrointestinal	Ribbon stools, severe abdominal distension, bilious vomiting, bloody diarrhea/rectal bleeding (without fissure).
Systemic	Failure to thrive, fever, unexplained weight loss.
Neurological/Anatomic	Absent anal/cremasteric reflex, lower extremity weakness, sacral dimple/hair tuft, gluteal cleft deviation, anteriorly displaced anus.

Physical Examination

• Abdomen: Palpable fecal mass in suprapubic/left lower quadrant, gaseous distension.
• Perineum: Assess anal position, patulous anus (suggests innervation disorder), fissures, skin tags, perianal excoriation.
• Digital Rectal Examination (DRE):
  • Indicated if diagnosis unclear, or to differentiate non-retentive fecal incontinence from overflow incontinence.
  • Functional Constipation: Enlarged ampulla filled with hard stool.
  • Hirschsprung Disease: Tight anal canal, empty ampulla, explosive expulsion of stool/air upon finger withdrawal (squirt sign).

Differentiating Functional Constipation vs. Hirschsprung Disease

Feature	Functional Constipation	Hirschsprung Disease
Onset	Beyond infancy (toddler/preschool).	Neonatal/Infancy.
Meconium Passage	Normal (<48 hours).	Delayed (>48 hours).
Encopresis / Soiling	Common.	Very Rare.
Stool Withholding	Common.	Rare.
Rectal Examination	Dilated ampulla, stool present.	Empty ampulla, tight sphincter, squirt sign.

DIAGNOSTIC INVESTIGATIONS

Diagnosis is primarily clinical. Testing reserved for alarm signs or refractory cases.

Laboratory Testing

• Indicated only with red flags.
• Tests: Thyroid function (TSH, free T4), Celiac screening (IgA tTG), serum calcium, electrolytes, lead levels.
• Sweat chloride test if cystic fibrosis suspected.

Radiological & Imaging Studies

• Abdominal X-Ray (AXR): Routine use discouraged. Poor inter- and intra-observer reliability. Does not correlate well with clinical symptoms.
• Contrast Enema (Barium): Evaluates anatomical abnormalities. Differentiates Hirschsprung disease (identifies transition zone, rectosigmoid ratio <1) from severe functional megarectum.
• MRI Spine: Indicated for neurological deficits or sacral anomalies to exclude tethered cord, lipoma, or spina bifida occulta.
• Ultrasonography: Emerging tool for measuring transrectal diameter to assess fecal loading non-invasively.

Functional and Motility Studies

• Anorectal Manometry (ARM): Measures sphincter pressures and rectoanal inhibitory reflex (RAIR). Absence of RAIR indicates need for rectal biopsy (excludes Hirschsprung disease). Detects pelvic floor dyssynergia.
• Colonic Transit Time: Utilizing radiopaque markers to classify constipation into anorectal retention, slow colonic transit, or normal transit.
• Colonic Manometry: Differentiates normal colonic physiology from myopathies/neuropathies. Evaluates presence of HAPCs. Guides surgical interventions.
• Rectal Suction Biopsy: Gold standard for Hirschsprung disease. Demonstrates absence of ganglion cells and presence of hypertrophied nerve trunks staining positive for acetylcholinesterase.

MANAGEMENT PROTOCOL

A multifaceted, stepwise approach is essential for successful treatment.

1. Education & Lifestyle Modifications

• Demystification: Reassure parents that incontinence is involuntary (overflow) and not willful.
• Toilet Training: Scheduled toilet sitting for 5–10 minutes post-prandially (utilizing gastrocolic reflex). Ensure proper posture (footstool for optimal anorectal angle). Implement positive reinforcement reward systems.
• Dietary: Maintain normal age-appropriate fiber intake (Age + 5 g/day) and adequate fluid intake. Avoid excessive fiber, which worsens bloating/pain. Consider 2-4 week cow’s milk elimination trial in refractory cases.

2. Fecal Disimpaction

Mandatory prerequisite before initiating maintenance therapy to prevent worsening overflow incontinence.

• Oral Route (Preferred): High-dose Polyethylene Glycol (PEG 3350) 1–1.5 g/kg/day for 3–6 days.
• Rectal Route: Phosphate enemas, sodium docusate, or glycerin suppositories. Provides faster relief but invasive and potentially traumatizing.
• Manual Disimpaction: Reserved for severe cases under general anesthesia.

3. Maintenance Pharmacotherapy

Objective: Achieve 1–2 soft, painless stools daily. Minimum duration 2 months; wean gradually once toilet training is complete and symptoms resolve.

Drug Class	Agent	Dosage	Side Effects & Notes
Osmotic	Polyethylene Glycol (PEG 3350)	0.3–0.8 g/kg/day.	First-line agent. Highly effective, safe. Side effects: Diarrhea, bloating.
Osmotic	Lactulose	1–2 g/kg/day (1-2 doses).	Alternative to PEG. First-line for infants <6 months. Side effects: Flatulence, cramping.
Osmotic	Milk of Magnesia	0.4–4.8 g/day (age-dependent).	Poor efficacy evidence. Risk of magnesium toxicity in renal impairment.
Lubricant	Mineral Oil (Liquid Paraffin)	1–3 mL/kg/day.	Contraindicated in infants <1 year or neurologically impaired (risk of lipoid pneumonia).
Stimulant	Senna	2.5–20 mg/day (age-dependent).	Rescue therapy or adjunct. Stimulates peristalsis. Side effects: Cramping.
Stimulant	Bisacodyl	5–10 mg/day.	Oral or suppository. Induces HAPCs. Effective for refractory cases.

4. Novel Pharmacological Agents (Refractory Disease)

• Lubiprostone: Chloride channel activator promoting intestinal fluid secretion. Shows clinical benefits in pediatric trials but requires further validation.
• Linaclotide: Guanylate cyclase C-receptor agonist. Promotes fluid secretion. Pediatric trials show efficacy but limited by dose-dependent diarrhea.
• Prucalopride: Highly selective 5-HT4 receptor agonist (prokinetic). Pediatric RCTs failed to show superiority over placebo, likely due to inability to overcome active stool withholding.

5. Non-Pharmacological Interventions

• Biofeedback: Visualizes anorectal dynamics to teach coordination. Corrects dyssynergia but fails to show long-term clinical benefit over conventional therapy.
• Pelvic Floor Physiotherapy: Emphasizes posture, effective straining, and sensation awareness. Shown to be more effective than standard medical care.
• Trans-anal Irrigation (TAI): Retrograde colonic flushing using a cone/catheter. Highly successful in neurogenic bowel and intractable functional constipation. Recommended prior to surgical consideration.
• Neuromodulation: Sacral Nerve Stimulation (SNS) involves surgical implantation of a pulse generator. Modulates pelvic afferents. Shows promise but carries high complication rates (infection, lead displacement). Transcutaneous posterior tibial nerve stimulation is an emerging non-invasive alternative.

6. Surgical Interventions

Reserved for extreme, intractable cases failing maximal medical management.

• Anal Botulinum Toxin Injection: Temporarily paralyzes internal anal sphincter, relieving resting tone. Highly effective in breaking the withholding cycle, though repeat injections may be needed.
• Antegrade Continence Enema (ACE/Malone Procedure): Appendicostomy or cecostomy allows antegrade flushing of the colon. High success rates (95% cleanliness) but risks stomal stenosis, leakage, and granulation tissue.
• Colonic Resection: Segmental or subtotal colectomy guided by colonic manometry. Extremely rare; reserved for severe localized colonic dysmotility or inertia.

PROGNOSIS & COMPLICATIONS

• Prognosis: Constipation is not self-limiting. Despite aggressive therapy, symptoms persist into adulthood in up to 25% of children. Long-term adherence to maintenance therapy is critical.
• Complications:
  • Encopresis (Fecal Incontinence): Social stigmatization, peer rejection, poor school performance.
  • Urinary Tract Sequelae: Chronic rectal distension compresses the bladder, leading to urinary incontinence, vesicoureteral reflux, urinary retention, and recurrent urinary tract infections.
  • Anorectal Pathology: Anal fissures resulting from hard stools, hemorrhoids, and rectal prolapse.
  • Psychosocial Impact: Significantly reduced Health-Related Quality of Life (HRQoL), increased anxiety, and family distress.